Changchun High-Tech Industry (Group) Co.,Ltd.(000661),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000661 Changchun High-Tech Industry (Group) Co.,Ltd.

Trading 12-23 10:59:12

93.92

-1.27

-1.33%

High95.10	Low93.86	Vol2.88M
Open95.08	D1 Closing95.19	Amplitude1.30%
Mkt Cap38.32B	Tradable Cap37.57B	Total Shares408.00M
T/O272.00M	T/O Rate0.72%	Tradable Shares400.00M
P/B1.69	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"Changchun High-Tech Industry (Group) Co.,Ltd.","latestPrice":93.92,"timestamp":1766458752000,"preClose":95.19,"halted":0,"volume":2881421,"delay":0,"changeRate":-0.0133,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"Trading","change":-1.27,"latestTime":"12-23 10:59:12","open":95.08,"high":95.1,"low":93.86,"amount":272000000,"amplitude":0.013,"askPrice":93.93,"askSize":12,"bidPrice":93.92,"bidSize":1,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1766460600000},"marketStatusCode":2,"adr":0,"adjPreClose":95.19,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":104.71,"lowLimit":85.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.69,"roa":"--","peRate":39.948958,"roe":"5.03%","epsLYR":6.42,"committee":-0.179063,"marketValue":38313000000,"turnoverRate":0.0072,"status":1,"floatMarketCap":37532000000},"requestUrl":"/m/hq/s/000661/tweets","defaultTab":"tweets","newsList":[{"id":"2591608218","title":"Changchun High-Tech Industry's Subsidiary Grants Yarrow Bioscience Worldwide Rights for Eye Disease Drug; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591608218","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591608218?lang=en_us&edition=fundamental","pubTime":"2025-12-16 13:41","pubTimestamp":1765863713,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry's  subsidiary, Shanghai Saizeng Medical Technology, agreed to grant Yarrow Bioscience exclusive worldwide rights for the GenSci098 injection project, according to a Shenzhen bourse filing on Tuesday.The drug is being studied for indications related to thyroid eye disease and Graves' disease.Saizeng Medical expects to receive an upfront payment of $120 million and milestone payments related to the drug's research and development and commercialization. The pharmaceutical company will also be entitled to $1.37 billion in milestone payments for the exclusive license and royalties of more than 10% for the drug's net sales.The biopharmaceutical company's shares jumped 4% during afternoon trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000661","BK0046","BK0028","BK0057","BK0239","BK0075","BK0188"],"gpt_icon":0},{"id":"2591646710","title":"Changchun High-Tech Industry Says Unit Expects to Receive $120 Mln in Upfront and Early Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646710?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:48","pubTimestamp":1765802929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL0U7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0239","BK0046","000661","BK0028","BK0075","BK0057"],"gpt_icon":0},{"id":"2591467526","title":"Changchun High-Tech Industry  Says Unit Signs Licensing Agreement for Gensci098 Injection Project With Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2591467526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591467526?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:44","pubTimestamp":1765802657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL0U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","000661","BK0046","BK0188","BK0057","BK0075","BK0239"],"gpt_icon":0},{"id":"2590360873","title":"China Includes Changchun High-Tech Industry's Growth Disorder, Anorexia Drugs in Insurance Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360873","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590360873?lang=en_us&edition=fundamental","pubTime":"2025-12-09 09:01","pubTimestamp":1765242100,"startTime":"0","endTime":"0","summary":"China has included Changchun High-Tech Industry's  two drugs in the country's national basic medical insurance catalog, according to a Tuesday filing with the Shenzhen bourse.Authorities approved for inclusion in the insurance program a growth hormone injection to treat endogenous growth hormone deficiency, growth disorders in girls due to Turner's hypogonadism, and for idiopathic short stature, the filing said.The other drug is for anorexia in AIDS and cancer patients, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0057","BK0188","BK0028","BK0075","BK0046","000661"],"gpt_icon":0},{"id":"1153111707","title":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1153111707","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153111707?lang=en_us&edition=fundamental","pubTime":"2025-12-08 16:58","pubTimestamp":1765184295,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","BK0057","BK0046","000661","BK0188","91272","BK0075"],"gpt_icon":0},{"id":"2586177272","title":"Changchun High-Tech Gets Green Light to Trial Bacterial Vaginosis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2586177272","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586177272?lang=en_us&edition=fundamental","pubTime":"2025-11-28 10:52","pubTimestamp":1764298350,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry Group  has secured approval from China's National Medical Products Administration to proceed with the clinical trial registration for its innovative drug, GenSci142 capsules.The drug, developed by the company's subsidiary Changchun Jinsai Pharmaceutical, is indicated for the treatment of bacterial vaginosis.The company claims that its GenSci142 capsules can \"directly destroy bacterial cell walls\" and \"rapidly kill the main pathogens of bacterial vaginosis.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","000661","BK0057","BK0028","BK0046","BK0075","BK0239"],"gpt_icon":0},{"id":"1174264473","title":"Changchun High-Tech Industry (000661.SZ): GenSci142 Capsule Receives Approval for Domestic Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1174264473","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174264473?lang=en_us&edition=fundamental","pubTime":"2025-11-27 17:00","pubTimestamp":1764234029,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (\"Jinsai Pharma\"), has received the \"Drug Clinical Trial Approval...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000661","91272","BK0046","BK0057","BK0188","BK0028","BK0239","BK0075"],"gpt_icon":0},{"id":"2584261586","title":"Changchun High-Tech Industry's Unit Gets Nod for GS3-007a Dry Suspension Clinical Trial; Shares Down 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584261586","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584261586?lang=en_us&edition=fundamental","pubTime":"2025-11-17 11:39","pubTimestamp":1763350773,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry's  unit, Changchun Jinsai Pharmaceutical, received the approval of China's National Medical Products Administration for the clinical trial application of GS3-007a dry suspension, according to a Shenzhen bourse filing on Saturday.The shares of the Chinese biopharmaceutical product manufacturer fell by less than 2% during Monday morning's trade.The drug is being developed as a treatment for patients with pediatric growth hormone deficiency.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0057","BK0188","000661","BK0046","BK0028","BK0075","BK0239"],"gpt_icon":0},{"id":"2584137666","title":"Changchun High-Tech Industry Gets Nod for GenSci140 for Injection Clinical Trial; Shares Down 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584137666","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584137666?lang=en_us&edition=fundamental","pubTime":"2025-11-17 11:30","pubTimestamp":1763350203,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry  obtained the approval of China's National Medical Products Administration for the clinical trial application of GenSci140 for injection, according to a Shenzhen bourse filing on Saturday.The Chinese biopharmaceutical product manufacturer's shares fell less than 2% during Monday's morning trade.The drug is being developed as a treatment for patients with advanced or metastatic solid tumors.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0057","BK0188","BK0046","BK0075","000661","BK0239","BK0028"],"gpt_icon":0},{"id":"1143591750","title":"Changchun High-Tech (000661.SZ) Plans Hong Kong IPO, CSRC Requests Additional Disclosures on Fund Usage","url":"https://stock-news.laohu8.com/highlight/detail?id=1143591750","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143591750?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:04","pubTimestamp":1763121863,"startTime":"0","endTime":"0","summary":"On November 14, China Securities Regulatory Commission (CSRC) released supplementary material requirements for overseas listings (November 10-14, 2025). The CSRC's international department disclosed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000661","91272","BK0188","BK0046","BK0028","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2583016521","title":"Changchun High-Tech's Unit Gets US FDA's Nod for GenSci143 for Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583016521","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583016521?lang=en_us&edition=fundamental","pubTime":"2025-11-14 14:31","pubTimestamp":1763101909,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved the clinical trial application of Changchun High-Tech Industry's  unit, Changchun Jinsai Pharmaceutical, for GenSci143 for injection, according to a Shenzhen bourse filing on Friday.The Chinese biopharmaceutical product manufacturer will be able to conduct clinical trials in the U.S. to test the drug as a treatment for advanced solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000661","BK0239","BK0188","BK0028","BK0046","BK0075","BK0057"],"gpt_icon":0},{"id":"2583580112","title":"China Approves Changchun High-Tech Industry Subsidiary's Clinical Trial for Diphtheria-Tetanus Jab","url":"https://stock-news.laohu8.com/highlight/detail?id=2583580112","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583580112?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:02","pubTimestamp":1762995722,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Changchun High-Tech Industry  subsidiary Changchun BECO Biotechnology's clinical trial for its diphtheria-tetanus combined vaccine for adults and adolescents.The vaccine is indicated for the prevention of simultaneously prevent pertussis, diphtheria, and tetanus in adolescents and adults aged 10 years and above, according to a Thursday filing with the Shenzhen bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000661","BK0188","BK0046","BK0028","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"1137543318","title":"Changchun High-Tech (000661.SZ): GenSci134 Injection Receives Approval for Domestic Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1137543318","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137543318?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:04","pubTimestamp":1762167854,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical Co., Ltd., has received the \"Drug Clinical Trial Approval Notice\" issued by the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0057","BK0188","000661","BK0046","BK0028","BK0075","91272","BK0239"],"gpt_icon":0},{"id":"2580225291","title":"Changchun High-Tech Industry's Unit Gets Nod to Conduct Clinical Trials on Growth Hormone Deficiency Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225291","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580225291?lang=en_us&edition=fundamental","pubTime":"2025-11-03 12:11","pubTimestamp":1762143110,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry's  unit, Changchun Jinsai Pharmaceutical, received approval from the Chinese drug administration to conduct clinical trials on the GenSci134 injection, according to a Shenzhen bourse disclosure on Saturday.The pharmaceutical company's shares dropped less than 4% during the Monday's morning trade.The drug is being developed as a treatment for growth hormone deficiency in both adults and children.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000661","BK0046","BK0057","BK0188","BK0239","BK0028","BK0075"],"gpt_icon":0},{"id":"1126490787","title":"Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1126490787","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126490787?lang=en_us&edition=fundamental","pubTime":"2025-10-31 17:30","pubTimestamp":1761903032,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0057","BK0188","000661","91272","BK0028","BK0075","BK0239"],"gpt_icon":0},{"id":"1118925011","title":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Reports Q3 Results: Net Profit Attributable to Shareholders Drops 58.23% YoY to RMB1.165 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1118925011","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118925011?lang=en_us&edition=fundamental","pubTime":"2025-10-30 23:48","pubTimestamp":1761839291,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) released its third-quarter report for 2025. During the first three quarters, the company achieved operating revenue of RMB9.807 billion,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000661","BK0057","BK0046","BK0239","91272","BK0028","BK0075","BK0188"],"gpt_icon":0},{"id":"2579611973","title":"Changchun High-Tech Industry Group Q3 Net Profit Down 83.0% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2579611973","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579611973?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:20","pubTimestamp":1761819609,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Changchun High-Tech Industry Group Co Ltd <000661.SZ>::*Q3 NET PROFIT DOWN 83.0% Y/Y  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-OCT-202510:06:33 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nRSD1673bt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0028","BK0188","BK0075","BK0239","BK0057","000661"],"gpt_icon":0},{"id":"2577335270","title":"Chinese Drug Administration Accepts Changchun High-Tech's Clinical Trial Application for GenSci142 Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2577335270","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577335270?lang=en_us&edition=fundamental","pubTime":"2025-10-22 11:42","pubTimestamp":1761104548,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Changchun High-Tech Industry's (SHE:000661) application to conduct clinical trials on GenSci142 capsules, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for bacterial vaginosis.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0046","000661","BK0028","BK0188","BK0239","BK0057","BK0075"],"gpt_icon":0},{"id":"2577726843","title":"Changchun High-Tech Industry Gets Regulatory Nod for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577726843","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577726843?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:01","pubTimestamp":1761026514,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry  subsidiary Jinsai Pharmaceutical received the approval of China's drug administrator to begin clinical trials in China for its GenSci139 injection.The drug, which targets cancer-related proteins EGFR and HER2, is intended for the treatment of advanced solid tumors, according to a Tuesday filing with the Shenzhen bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0239","BK0046","BK0075","BK0057","000661","BK0028"],"gpt_icon":0},{"id":"1113752779","title":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ): Clinical Trial Approval for GenSci139 Injectable Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1113752779","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113752779?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:54","pubTimestamp":1760957666,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (\"JinSai Pharmaceutical\"), has received the \"Drug Clinical Trial...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000661","BK0028","BK0075","91272","BK0057","BK0239","BK0046","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","stockEarnings":[{"period":"1week","weight":0.034},{"period":"1month","weight":-0.0376},{"period":"3month","weight":-0.1974},{"period":"6month","weight":-0.0144},{"period":"1year","weight":-0.0348},{"period":"ytd","weight":-0.0197}],"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","perCapita":"3840股","boardName":"医药制造业","registeredCapital":"40793万元","compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"survey":"　　长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","serverTime":1766458753191,"listedPrice":8.8,"stockholders":"104055人(较上一季度减少4.63%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Changchun High-Tech Industry (Group) Co.,Ltd.(000661),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Changchun High-Tech Industry (Group) Co.,Ltd.(000661) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Changchun High-Tech Industry (Group) Co.,Ltd.,000661,Changchun High-Tech Industry (Group) Co.,Ltd.股票,Changchun High-Tech Industry (Group) Co.,Ltd.股票老虎,Changchun High-Tech Industry (Group) Co.,Ltd.股票老虎国际,Changchun High-Tech Industry (Group) Co.,Ltd.行情,Changchun High-Tech Industry (Group) Co.,Ltd.股票行情,Changchun High-Tech Industry (Group) Co.,Ltd.股价,Changchun High-Tech Industry (Group) Co.,Ltd.股市,Changchun High-Tech Industry (Group) Co.,Ltd.股票价格,Changchun High-Tech Industry (Group) Co.,Ltd.股票交易,Changchun High-Tech Industry (Group) Co.,Ltd.股票购买,Changchun High-Tech Industry (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Changchun High-Tech Industry (Group) Co.,Ltd.(000661),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Changchun High-Tech Industry (Group) Co.,Ltd.(000661) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction